We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

CERTEST BIOTEC

Certest Biotec, S.L. develops and manufactures IVD products in the human clinical testing field, including rapid test... read more Featured Products: More products

Download Mobile App





CerTest Demonstrates New VIASURE RT-PCR Complete Solution at MEDICA 2022

By LabMedica International staff writers
Posted on 13 Nov 2022

Like every year, mid-November, CerTest Biotec (Zaragoza, Spain) is participating in the MEDICA fair in Düsseldorf to close its annual exhibitions tour, as this is the largest and most important event in the health sector, and which brings together several thousand exhibitors from more than 70 countries. More...

Once again in the face-to-face format, this year’s edition of MEDICA represents four days of exhibition, knowledge transfer and networking for professionals and companies.

At MEDICA 2022, Certest is presenting several novel products for research and diagnosis, such as its new VIASURE RT-PCR Complete Solution, along with equipment and reagents for CLIA. The VIASURE Complete Solution comprises RNA/DNA pathogen extraction kits, nucleic acid extraction and PCR set-up system, RT PCR detection kits, RT PCR system and software, and RNA viral particles. VIASURE Complete Solution includes the VIASURE V-FLEX system, a new fully automated solution in molecular biology for nucleic acid extraction, purification and PCR set-up from biological matrix and samples. The instrument has been designed with flexible configuration, in order to meet different user needs.

Also a part of VIASURE Complete Solution is the VIASURE V-Lab96 Advanced RT PCR System with 96-well block for high sample throughput in diagnostic lab applications. VIASURE V-Lab96 allows users to analyze 96 samples simultaneously for qualitative and quantitative PCR. Also included is the VIASURE V-Smart software for the analysis and interpretation of VIASURE RT PCR assays. The VIASURE V-Smart software facilitates the conversion of the PCR raw data into test results with minimal manual intervention.

VIASURE DNA/RNA Pathogen Extraction Kit allows extraction from various biological samples such as swabs, saliva, sputum, bronchoalveolar lavages, fecal and urine samples. The kit is based on magnetic particles, which allows its automation for high throughput analysis, reducing hands-on-time and improving reproducibility. The extraction kit has been optimized for two types of magnetic separation methods: VIASURE V-Flex and KingFisher Flex (other platforms ongoing). Additionally, VIASURE Real Time PCR Detection Kits allow for simultaneous detection of multiple targets in a broad range of multiplexing diagnostic panels, including in the area of antimicrobial resistance.

Related Links:
CerTest Biotec


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
cDNA Synthesis Kit
Ultimate cDNA Synthesis Kit
New
Biochemistry Analyzer
Chemi+ 8100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Non-coding RNAs CBR3-AS1 and PCA3 can be utilized as therapeutic targets and prognostic biomarkers in gastric cancer (Photo courtesy of Adobe Stock)

Promising Molecular Markers Support Earlier Diagnosis of Gastric Cancer

Late detection continues to make gastric cancer one of the leading causes of cancer-related deaths globally. With improved early detection tools urgently needed, researchers have now identified two long... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.